University of Essen, Children's Hospital, Dep. of Pediatric Pulmonology
Essen, North Rhine-Westphalia, 45122, Germany
NCT Number: NCT01981915
Patients with underlying neuromuscular disorder (NMD) often suffer from weakness in the inspiratory and expiratory muscles. Consequently they do not have the strength to generate the minimum flow of 160 to 300 liters/minute for an efficient cough function. The restricted cough function allows secretion to accumulate, which in turn causes narrowing of the airway lumen and makes ventilation of the neuromuscular patient even more difficult. The patient's susceptibility to infection increases again and the vicious circle repeats itself. Severe secretion retention may even lead to ventilator failure. Effective secretion and cough management instead reduces the risk for stay in hospital. Therefore, secretion and cough management is a mandatory part of the therapeutic concept for treating patients with neuromuscular disease.
The therapeutic efficacy of the Lung Insufflation Assist Maneuver(LIA) integrated in the ventilator VENTIlogic LS-plus manufactured by Weinmann GmbH+Co KG was studied in a pilot study carried out by the Dep. for Pediatric Pulmonology and Sleep Medicine at the University Hospital of Essen/Germany in cooperation with Research & Development at Weinmann GmbH &Co KG, Germany . The objective of the pilot study was to examine the therapeutic efficacy of LIAM as a cough support function in patients with neuromuscular disease and indications for mechanical ventilation.
We hypothesized that i) a certain insufflation maneuver pressure may be optimal to achieve the highest individual peak cough flow and ii) that this pressure is below the pressure needed to achieve the maximum insufflation capacity. We define the lowest insufflation capacity at which the best individual PCF can be achieved as optimum insufflation capacity (OIC). The study was performed using two different techniques in order to demonstrate that findings are not dependent on maneuver details but are rather based on effects of maneuver pressure. The protocol was limited to techniques which do not require breath stacking: i) insufflation with an Intermittend Positive Pressure (IPPB) device and ii) with the VENTIlogic LS using LIAM.
Looking for future studies?
Notify Me6 year and older
All sexes
Interventional
Not applicable
Essen, North Rhine-Westphalia, 45122, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
Other names: Intermittent Positive Pressure Breathing = IPPB
Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
Other names: LIAM = Lung Insufflation Assist Maneuver
Time frame: change of lung volume with the procedure; during hospital stay on average 3 days
Lung volume was measured during spontaneous breathing and after a lung insufflation assist maneuver.
Time frame: change of peak cough flow with the procedure; during hospital stay on average 3 days
Peak cough flow was measured during spontaneous breathing and after a lung insufflation assist maneuver.
Universität Duisburg-Essen
Other
Optimum Insufflation Capacity and Peak Cough Flow Augmentation in Patients With Neuromuscular Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03689660
Biofeedback, Central Nervous System Diseases
Izmir, Balcova, Turkey (Türkiye)
View Trial DetailsNCT01931644
ADD/ADHD, Abnormalities, Multiple
Los Angeles, California, United States
View Trial DetailsNCT04335942
Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Garches, France
View Trial DetailsNCT01422200
Central Nervous System Diseases, Congenital Muscular Dystrophy
View Trial Details